Development of cinchonine niosomes delivery system as hair fertilizer

Year 2025, Volume: 29 Issue: 6, 2298 - 2307, 02.11.2025

Hariyanti Hariyanti , Sasanti T. Darijanto

https://doi.org/10.12991/jrespharm.1797779

Abstract

Cinchonine (CN), a Cinchona alkaloid, has activity as a hair fertilizer. CN is practically insoluble in water, and causes low penetration into hair follicles and dermal papilla. Therefore, CN requires a delivery system that is able to improve penetration. Niosome is a delivery system that can improve penetration by increasing solubility and reducing particle size. Objective of this study is to develop a CN-niosomes delivery system as a hair fertilizer. CNniosomes were made using the thin film hydration (optimization of sorbitan monostearate, CN, and cholesterol). Characterization includes size, PDI, and entrapment efficiency (EE). The CN-niosome stability test was carried out at temperatures of 30±2oC/RH 75±5% and 40±2oC/RH 75±5% for 28 days with test parameters of size, PDI and EE. In vivo tests include irritation tests using New Zealand male rabbits with observation intervals of 1, 24, 48 and 72 hours and hair growth activity tests using Hartley male guinea pigs for 14 days with observation intervals of 2 days. Results: Formulation of CN-niosom is sorbitan monostearate 100 μmol, CN 0.03% w/v and cholesterol 15% from the amount of surfactant deionized water up to 10 mL. Characterization of size 153.23±1.24nm, PDI 0.290±0.05 and EE 84.42±0.07%. The stability test showed that CN-niosomes were less stable during storage as seen from the fluctuation in size of 200– 350nm, PDI of 0.250–0.450 and EE of 83–85%. Irritation test results show that CN and excipients are non-irritant. Activity test showed that CN-niosomes are able to increase hair growth as seen from the hair length parameters of the test group which increased significantly compared to the control group (p<0.05). CN-niosome has the potential as an agent to accelerate hair length growth with a good safety profile (non-irritant).

Keywords

Cinchonine , niosomes , hair fertilizer , dermal papilla

References

• [1] Satheeshan K, Seema B, Manjusha MA. Development and evaluation of VCO based herbal hair tonic. J Pharmacogn Phytochem. 2020; 9 (2): 485–493.
• [2] Hariyanti H, Mauludin R, Sumirtapura YC, Kurniati NF. Activity and safety of cinchonine nanostructured lipid carriers as a hair growth stimulant in mice model of androgenetic alopecia. Sains Malaysiana. 2023; 52 (6): 1671–1683. http://doi.org/10.17576/jsm-2023-5206-05.
• [3] Lana L, Ascenso A. New Trends in Anti-Aging Skin Care. In: Carrier-Mediated Dermal Deliv. 2018. https://doi.org/10.4324/9781315364476-1.
• [4] Ascenso A, Simões S, Ribeiro H. Carrier-mediated dermal delivery: Applications in the prevention and treatment of skin disorders, 2017. https://doi.org/10.4324/9781315364476.
• [5] Hariyanti H, Mauludin R, Sumirtapura YC, Kurniati NF. A Review: Pharmacological activities of quinoline alkaloid of Cinchona sp. Biointerface Res App Chem. 2022; 13 (4): 1–13. https://dx.doi.org/10.33263/BRIAC134.319.
• [6] Tewari A, Tewari S. Synthesis of Medicinal Agents from Plants. Elsevier, United States, 2018. https://dx.doi.org/10.1016/C2016-0-01140-3
• [7] Geyfman M, Plikus MV, Treffeisen E, Andersen B, Paus R. Resting no more: re-defining telogen, the maintenance stage of the hair growth cycle. Biol Rev Camb Philos Soc. 2015;90(4):1179-1196. https://doi.org/10.1111/brv.12151.
• [8] Hoogevest P, Fahr A. Phospholipids in Cosmetic Carriers. In: Nanocosmetics. Phospholipid Research Center, Germany, 2019. https://doi.org/10.1007/978-3-030-16573-4_6.
• [9] Manosroi J, Chankhampan C, Chaikul P, Manosroi W, Manosroi A. Transfollicular enhancement of methyl myristate loaded in cationic niosomes incorporated in hair lotion. J Microencapsul. 2016;33(6):585-594. https://dx.doi.org/10.1080/02652048.2016.1228705
• [10] Das P, Qureshi D, Paul S, Mohanty B, Anis A, Verma S, Wilczyński S, Pal K. Effect of sorbitan monopalmitate on the polymorphic transitions and physicochemical properties of mango butter. Food Chem. 2021 Jun 15;347:128987. https://doi.org/10.1016/j.foodchem.2020.128987.
• [11] Chen S, Hanning S, Falconer J, Locke M, Wen J. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019;144:18-39. https://doi.org/10.1016/j.ejpb.2019.08.015.
• [12] Elmowafy E, El-Derany MO, Biondo F, Tiboni M, Casettari L, Soliman ME. Quercetin Loaded Monolaurate Sugar Esters-Based Niosomes: Sustained Release and Mutual Antioxidant-Hepatoprotective Interplay. Pharmaceutics. 2020;12(2):143. https://doi.org/10.3390/pharmaceutics12020143.
• [13] Hariyanti H, Kurniati NF, Sumirtapura YC, Mauludin R. Development and validation of an analytical method for the determination of nanostructured lipid carrier’s cinchonine used direct method modified by liquid-liquid extraction using high-performance liquid chromatography. J Res Pharm. 2023; 27(2): 913-923. https://dx.doi.org/10.29228/jrp.371
• [14] Leveque M, Mas C, Haure M, Lejeune O, Duplan H, Castex-Rizzi N, Bessou-Touya S. 601 Hair growth properties of Cinchona succirubra extract, Leontopodium alpinum extract and Manganese PCA in human hair follicle dermal papilla cells. J Invest Dermatol. 2021; 141: S104. https://dx.doi.org/10.1016/j.jid.2021.02.629
• [15] Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018; 59(2): 455-467.
• [16] Choi BY. Targeting Wnt/β-Catenin Pathway for Developing Therapies for Hair Loss. Int J Mol Sci. 2020;21(14):4915. https://doi.org/10.3390/ijms21144915.
• [17] Hawkshaw NJ, Hardman JA, Alam M, Jimenez F, Paus R. Deciphering the molecular morphology of the human hair cycle: Wnt signalling during the telogen-anagen transformation. Br J Dermatol. 2020;182(5):1184-1193. https://doi.org/10.1111/bjd.18356.
• [18] WHO. Q1F Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. 2018; Annex. 10: 1-44. https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf
• [19] ICH. Q1A(R2), ICH Harmonısed Trıpartıte Guıdelıne, Stabılıty Testıng of New Drug Substances And Products. San Diego, USA, 2005; 1-24. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
• [20] Zothanpuıı F, Rajesh R, Selvakumar K. A revıew on stabılıty testıng guıdelınes of pharmaceutıcal products. Asian J Pharm Clin Res. 2020; 13(10): 3-9. https://doi.org/10.22159/ajpcr.2020.v13i10.38848